Clinical trials: Cancer, Bladder
Cancer, Cancer Metastatic
Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients
This is a single-arm, prospective, interventional study in cancer survivors and patients to examine the feasibility of a mobile health application, Elly (Elly Health Inc.), to reduce levels of anxiety, stress, loneliness, and…
- Conditions
- Cancer, Cancer Metastatic, Neoplasms, Breast Cancer
- Trial name
- NCT04604158
- Testing
- Elly Mobile Phone Application
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Gillian Gresham
Muscle Invasive Bladder Urothelial Carcinoma
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Patients with MIBC will receive 3 cycles (C1-C3) of induction enfortumab vedotin plus pembrolizumab followed by restaging including MRI of the bladder, urine cytology, and cystoscopy with TURBT of any visible tumor and/or…
- Trial name
- NCT06809140
- Testing
- Enfortumab vedotin, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Matthew Galsky
Bladder Cancer
Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer
The purpose of this study is to evaluate efficacy of gemcitabine and cisplatin combined with either radical cystectomy or radiotherapy in the treatment of bladder cancer.
- Trial name
- NCT00490880
- Testing
- gemcitabine, cisplatin, radical cystectomy
- Where
- Poland
- Volunteers
- 2 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor
A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)
The Purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hSTC810 monotherapy in participants with advanced solid tumors.
- Trial name
- NCT05231746
- Testing
- hSTC810
- Where
- 5 sites in United States, South Korea
- Volunteers
- 47 people
- Sponsor
- STCube, Inc.
Muscle-invasive Bladder Urothelial Carcinoma
A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer
The purpose of this study is to evaluate whether Enfortumab Vedotin in combination with Pembrolizumab can achieve a clinical response that preserves the bladder and avoids the need for cystectomy or radiation therapy in patients…
- Trial name
- PRESERVE (NCT07822373)
- Testing
- Enfortumab vedotin, Pembrolizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Utah
Urothelial Carcinoma
Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation
This is a prospective, open, single center clinical study of vidicizumab combined with local radiotherapy as bladder conserving therapy in patients with muscle invasive bladder urothelium cancer with HER-2 expression (IHC 2+or…
- Trial name
- NCT05912205
- Testing
- Disitamab Vedotin, radiotherapy
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Urinary Tract Infection, Prostatitis
FOsfomycin for Male Urinary Tract Infection
Male urinary tract infections (MUTI) are often less recognised compared to those in women. French clinical guidelines practices recommend the use of antibiotics called fluoroquinolones, which are highly effective in treating…
- Conditions
- Urinary Tract Infection, Prostatitis, Cystitis
- Trial name
- FOMUTI (NCT06822751)
- Testing
- Fosfomycun-trometamol
- Where
- France
- Volunteers
- 138 people
- Sponsor
- University Hospital, Rouen
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
This study will evaluate the safety and efficacy of intravesical administration of detalimogene (EG-70) in the bladder and its effect on bladder tumors in patients with NMIBC.
- Conditions
- Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
- Trial name
- NCT04752722
- Testing
- EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy)
- Where
- 102 sites in United States, Australia and 8 more
- Volunteers
- 350 people
- Sponsor
- enGene, Inc.
Bladder Cancer
Steps to Eliminate Postoperative Problems
Radical cystectomy with urinary diversion is associated with substantial perioperative morbidity, including deep venous thrombosis, prolonged ileus, and postoperative functional decline.
- Trial name
- STEPP (NCT02880176)
- Testing
- Financial Incentive to Increase Ambulation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Pennsylvania
Urinary Bladder Tumour, MRI
Tumor Staging T of Bladder Tumours: Correlation of MRI and Anatomopathologic Analysis
Urinary bladder tumors with a frequency of 13000 new cases a year, have a heterogeneity in terms of survival according to the stage of local flooding. This is an aggressive tumor because of the potential muscular infiltration.
- Conditions
- Urinary Bladder Tumour, MRI, Invasion, Diagnosis
- Trial name
- IRMAA (NCT05464576)
- Testing
- MRI
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Clermont-Ferrand
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating…
- Trial name
- NCT00083213
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Urothelial Carcinoma
Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy
In cohort 1 of this study, we used an attenuated schedule of neoadjuvant ipilimumab and nivolumab. In the multicenter extension (cohort 2), 30 patients were randomized between two neoadjuvant treatment schemes, both based upon an…
- Trial name
- NABUCCO (NCT03387761)
- Testing
- Ipilimumab, Nivolumab
- Where
- 3 sites in Netherlands
- Volunteers
- 54 people
- Sponsor
- The Netherlands Cancer Institute
Carcinoma in Situ of Bladder
Retrospective Chart Review of Valstar
This is an observational study involving a retrospective review of medical records of adult patients who have been treated with intravesical valrubicin for bladder carcinoma in situ (CIS) since October 2009.
- Trial name
- NCT01304173
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Bladder Neoplasms
Bladder Cancer Patient-Reported Outcomes
The purpose of this study is to identify aspects of the bladder cancer (BlCa) survivorship experience that differ by clinical risk at diagnosis.
- Trial name
- NCT01090388
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Baylor College of Medicine
Bladder Cancer, Urothelial Carcinoma
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
The purpose of this study is to measure the effect of IPI-549 in combination with nivolumab when compared to nivolumab monotherapy in advanced urothelial cancer patients.
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Solid Tumor, Advanced Cancer
- Trial name
- NCT03980041
- Testing
- IPI-549 (eganelisib), Nivolumab
- Where
- 29 sites in United States, Czechia and 5 more
- Volunteers
- 49 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Non-muscle-invasive Bladder Cancer, NMIBC
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer utilizing focal injections with or without laser application.
- Conditions
- Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms
- Trial name
- NCT05483868
- Testing
- AU-011, AU-011 in Combination with Medical Laser Adminstration, AU-011 in Combination with Medical Laser Administration
- Where
- 19 sites in United States, Australia
- Volunteers
- 55 people
- Sponsor
- Aura Biosciences
Cognitive Decline, Urinary Bladder Cancer
Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor
Bladder tumor is one of the most widespread tumors in the world, with increasing prevalence at the global level. One of the procedures in patients with bladder tumors is transurethral resection of the bladder (TURM) most often…
- Conditions
- Cognitive Decline, Urinary Bladder Cancer, Frail, Biomarker
- Trial name
- NCT07165236
- Where
- Croatia
- Volunteers
- 42 people
- Sponsor
- Osijek University Hospital
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00310011
- Testing
- cisplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- Wake Forest University Health Sciences
Bladder Cancer
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
This is an international, multicenter, double-blind, placebo-controlled, randomized study. All eligible patients entering the open label phase of the study will receive a single immediate instillation of apaziquone (4 mg in 40 mL…
- Trial name
- NCT01469221
- Testing
- Apaziquone
- Where
- 29 sites in United States, Czechia and 2 more
- Volunteers
- 47 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Advanced Urothelial Carcinoma
Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer
Patients with metastatic bladder cancer are usually treated with chemotherapy. If their cancers do not progress after chemotherapy, they can be enrolled into this study and receive a standard-of-care immunotherapy medication…
- Trial name
- NCT05687721
- Testing
- copanlisib, Avelumab
- Where
- United States
- Sponsor
- VA Office of Research and Development
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.